Below are the most recent publications written about "Peroxisome Proliferator-Activated Receptors" by people in Profiles.
-
Shetty A, Syn WK. Current treatment options for nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2019 05; 35(3):168-176.
-
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 07; 374(14):1321-31.
-
Aseem O, Barth JL, Klatt SC, Smith BT, Argraves WS. Cubilin expression is monoallelic and epigenetically augmented via PPARs. BMC Genomics. 2013 Jun 18; 14:405.
-
He YQ, Ma GY, Peng JN, Ma ZY, Hamann MT. Liver X receptor and peroxisome proliferator-activated receptor agonist from Cornus alternifolia. Biochim Biophys Acta. 2012 Jul; 1820(7):1021-6.
-
Wang D, DuBois RN. Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am. 2010 Sep; 39(3):697-707.
-
Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Maruyama T, Kawamori T. Inhibition of prostaglandin E(2) signaling through the EP(1) receptor does not affect prostacyclin production in human endothelial cells. Prostaglandins Other Lipid Mediat. 2009 Nov; 90(1-2):31-6.
-
Nareika A, Maldonado A, He L, Game BA, Slate EH, Sanders JJ, London SD, Lopes-Virella MF, Huang Y. High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin. J Periodontal Res. 2007 Feb; 42(1):31-8.